INTRODUCTION
============

Hepatitis C virus (HCV) infection causes acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC) [@B1]. HCV is also a major causative agent of HCC in Japan [@B2]. HCV is a positive-sense single stranded RNA virus with \~9.6 kb length, belonging to the genus Hepacivirus, a member of*the family Flaviviridae*. It is known that there exist at least 6 main genotypes of HCV [@B3]. These approximately equidistant genetic groups each contain a variable number of more closely related, genetically and epidemiologically distinct "subtypes". Genotypes differ from each other by 31 to 33% at the nucleotide level, compared with 20 to 25% between subtypes [@B3]. In Japan, HCV genotype 1b, 2a and 2b, respectively, are observed in \~70, 20 and 10% of HCV-infected patients [@B4].

Treatment with peginterferon plus ribavirin for 24 weeks leads to 70-80% sustained virological response (SVR) in treatment-naïve patients infected with HCV genotype 2 [@B5]-[@B7]. Combination of peginterferon with ribavirin for 24 weeks is the current standard of care (SOC) for treatment-naïve patients infected with HCV genotype 2 or 3. Some selected HCV genotype 2-infected patients achieved SVR with treatment periods shorter than 24 weeks [@B5]-[@B9]. However, in treatment-naïve patients infected with HCV genotype 1, treatment with peginterferon plus ribavirin for 48 weeks leads to only \~50% SVR [@B7]. Thus, HCV genotype is one of the important factors influencing the outcome of interferon treatments [@B7],[@B10].

Retreatment of chronic hepatitis C patients failing to achieve SVR with combination peginterferon plus ribavirin could only obtain 10 to 15% SVR in non-responders and 40 to 50% SVR in relapsers [@B11]. In North America and European countries, retreatment for HCV genotype 2 or 3 patients failing to achieve SVR with combination peginterferon plus ribavirin could lead to 37 to 46% SVR in non-responders and 52 to 63% in relapsers [@B12], [@B13], even though retreatment with SOC was performed for 48 weeks. In our previous study [@B14], we observed that retreatment for HCV genotype 2 Japanese patients who failed to achieve SVR with combination peginterferon alfa-2b plus ribavirin for 16, 24 or 48 weeks resulted in 71.4% SVR, but the proportions of non-responders and relapsers were unclear and HCV RNA was measured with COBAS AMPLICOR HCV Monitor Test v. 2.0 (range: 0.5 - 850 kIU/mL) (Roche Diagnostics, Tokyo, Japan).

In the present study, we investigated 29 HCV genotype 2-infected Japanese patients who had been previously treated and failed to clear HCV. We retreated them with peginterferon alfa-2a plus ribavirin and measured HCV RNA with the more sensitive COBAS TaqMan HCV test (Roche) to assess the efficacy and safety of peginterferon alfa-2a with ribavirin in patients who had failed previous therapy in clinical practice. We focused on 3 females retreated with peginterferon alfa plus ribavirin and resulting in non-SVR, in whose sera a single very low-titer fluctuation of HCV RNA from negative to positive was detected after HCV RNA had been undetected. This would indicate that treatment with SOC should be stopped in HCV genotype 2 female patients with these features.

MATERIALS AND METHODS
=====================

Patients
--------

Patients were recruited from Chiba University Hospital and 29 hospitals in Chiba, Ibaraki, and Saitama Prefectures between March 2008 and September 2011. Patients were eligible if they met the following inclusion criteria: (i) infected with HCV genotype 2 alone, (ii) age ≥ 20 years, (iii) diagnosed as chronic hepatitis C, (iv) negative for HBs antigen, (V) negative for human immunodeficiency virus, (vi) no autoimmune liver diseases, (vii) no severe renal disease, (viii) no severe heart disease, (ix) no mental disorders, (x) no current intravenous drug abuse, and (xi) no pregnancy. Thirty-four of the patients had previously been included in an investigation of the incidence of HCC during and immediately after peginterferon alfa-2a and ribavirin treatment in patients with chronic hepatitis C in Japan [@B2].

Study design
------------

We recruited previously treated patients infected with HCV genotype 2. In Japan, combination therapy for treatment-naïve patients infected with HCV genotype 2 was not supported by the Japanese health insurance system at that time [@B15]. Concerning previously treated patients, they had to have failed previous treatment with either conventional interferon monotherapy, peginterferon monotherapy, conventional interferon/ribavirin combination therapy, or peginterferon/ribavirin combination therapy, different from the previous study by Sherman et al. [@B12]. Twenty-nine consecutive patients were enrolled in this study. Informed consent was obtained from all patients prior to enrolment. The Ethics Committee of Chiba University School of Medicine approved the study protocol. In this study, 180 μg of peginterferon alfa-2a per week plus 600-800 mg ribavirin per day were usually given in the treatment of patients for as long as 24, 48, or 72 weeks, according to the patient\'s will, as combination therapy for retreated patients infected with HCV genotype 2 was supported for only 24 weeks by the Japanese health insurance system at that time [@B15]. Clinical and laboratory assessments were performed at least every 4 weeks during treatment and a 12-week follow-up period. Adverse events were noted by oral inquiry (patient interview), physical examinations and laboratory tests.

Determination of HCV RNA titers and HCV genotype
------------------------------------------------

Serum HCV RNA titer was measured using COBAS TaqMan HCV test (Roche), with levels ranging from 1.2 to 7.8 log IU/mL [@B16]. HCV genotype was determined by the antibody serotyping method of Tukiyama-Kohara et al. [@B17],[@B18]. According to this assay, HCV serotypes 1 and 2 correspond to HCV genotypes 1a/1b and 2a/2b [@B3]. HCV RNA titer and HCV genotype were determined before treatment, and HCV RNA was measured every 4 weeks before, during, and for at least 24 weeks after the end of treatment.

Serum liver function tests and hematology tests
-----------------------------------------------

Serum aminotransferase concentrations, other liver function tests and hematology tests were performed according to standard methods every 1 to 3 months before, during, and for at least 24 weeks after the end of treatment.

Assessment of efficacy
----------------------

SVR was defined as undetectable serum HCV RNA at 24 weeks after the end of treatment. Relapse was defined as undetectable HCV RNA at the end of therapy, followed by the reappearance of HCV RNA [@B11]. Non-response was defined as detectable HCV RNA at the end of therapy. Patients with undetectable HCV RNA within the initial 4 weeks of treatment were considered to have had rapid virological response (RVR). Patients who had undetectable HCV RNA within the initial 12 weeks of treatment were considered to have had complete early virological response (cEVR) (described as EVR in this article) [@B16].

Statistical analysis
--------------------

Data were expressed as mean ± standard deviation (SD). Differences were evaluated by Student\'s *t*-test, chi-square test, or Fisher\'s exact test. P \< 0.05 was considered statistically significant.

RESULTS
=======

Patient characteristics
-----------------------

The characteristics of the 29 patients in the present study are shown in Table [1](#T1){ref-type="table"}. They had a history of peginterferon/conventional interferon with or without ribavirin, and 4 were unknown regarding previous treatment response (Table [1](#T1){ref-type="table"}). In these 29 patients, 3 received conventional interferon monotherapy, 10 peginterferon alfa-2a monotherapy, 12 peginterferon alpha-2b plus ribavirin, 3 peginterferon alfa-2a plus ribavirin, and 1 had details unknown. HCV RNA levels (≥5log IU/mL, \<5log IU/mL, and unknown) were 24, 4 and 1, respectively. Concerning virological response, 18 (62.0%) had SVR, 9 (31.0%) relapsed, and 2 (6.8%) discontinued treatment due to side effects.

Comparison of SVR patients with non-SVR patients among previously treated patients
----------------------------------------------------------------------------------

Next, we compared 18 SVR patients with 11 non-SVR patients among the previously treated patients (Table [2](#T2){ref-type="table"}). The platelet count of SVR patients tended to be higher than that of non-SVR patients (*P* = 0.061). We did not see any differences in the baselines of other factors and treatment responses (Table [2](#T2){ref-type="table"}). In the 18 SVR patients previously treated, 3 received conventional interferon monotherapy, 5 peginterferon alfa-2a monotherapy, 7 peginterferon alpha-2b plus ribavirin, 2 peginterferon alfa-2a plus ribavirin and 1 with details unknown. In the 11 non-SVR patients previously treated, 5 received peginterferon alfa-2a monotherapy, 5 peginterferon alpha-2b plus ribavirin, and 1 peginterferon alfa-2a plus ribavirin. Concerning previous treatment response of the 29 previously treated patients, 18 were relapsers, 7 non-responders, and 4 had details unknown. In the 18 SVR patients, 12 were relapsers, 4 non-responders, and 2 had details unknown. In 11 non-SVR patients, 6 were relapsers, 3 non-responders, and 2 had details unknown.

Previous treatment response and SVR rates in HCV genotype 2 retreated patients
------------------------------------------------------------------------------

The relationship between previous treatment response and SVR rates of HCV genotype 2 retreated patients is shown in Table [3](#T3){ref-type="table"}. In 1 patient previously treated with peginterferon plus ribavirin and non-response, treatment was discontinued due to side effects by \~8 weeks and SVR was not obtained. Of 13 patients previously treated with peginterferon plus ribavirin who had relapsed, 2 discontinued treatment due to side effects by \~8 weeks.

Female cases retreated, in whose sera a single very low-titer fluctuation of HCV RNA from negative to positive was detected after HCV RNA had been undetected
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Furthermore, we tried to determine the clinical features of non-SVR HCV genotype 2 patients retreated with peginterferon alfa-2a plus ribavirin. We noticed 3 females retreated with peginterferon alfa-2a plus ribavirin and resulting in non-SVR, in whose sera a single very low-titer fluctuation of HCV RNA from negative to positive was detected after HCV RNA had been undetected (Figure [1](#F1){ref-type="fig"}). HCV RNA finally relapsed in all 3 cases. Treatment with SOC might need to be stopped in HCV genotype 2 female patients with these features.

DISCUSSION
==========

In the present study, we focused on the virological response in HCV genotype 2-infected Japanese patients retreated with peginterferon alfa-2a plus ribavirin. We did not observe any differences in baseline background between SVR patients retreated and non-SVR patients retreated, although we must admit that the number of patients was small. However, during this study, we did find 3 females who did not obtain SVR by the retreatment and had unique features. That is, in their sera, a single very low-titer fluctuation of HCV RNA from negative to positive was detected after HCV RNA had been undetected (Figure [1](#F1){ref-type="fig"}). These 3 cases did not discontinue peginterferon alfa-2a or ribavirin. In Figure [1](#F1){ref-type="fig"}, cases 1 and 2 had reduced peginterferon alfa-2a but not reduced ribavirin. On the other hand, case 3 had reduced ribavirin due to anemia, but did not have a reduction of peginterferon alfa-2a. In cases 2 and 3, adherence (≥80/≥80/≥80) [@B19] based on the calculation at 48 weeks was not lower. These 3 cases were relapsers and seemed different from non-responders having anti-interferon-alfa neutralizing antibody [@B20]. We do not know the exact reasons at this time.

In the present study, 44% of patients had rapid virological response (RVR) and 89% of the patients had EVR (cEVR) in the retreated genotype 2 chronic hepatitis C patients with an SVR (Table [2](#T2){ref-type="table"}). These results were concordant with previous studies. However, 89% of the non-SVR patients also had EVR (Table [2](#T2){ref-type="table"}). Among the 8 non-SVR patients, 3 had lower adherence (≥80/≥80/≥80) (data not shown). In the present study, the adherence rates were quite low (44% in patients with SVR, and 54% in patients without SVR). In certain cases, lower adherence may be one of the reasons for non-SVR.

For HCV genotype 1 patients, direct acting antivirals (DAAs) such as telaprevir and boceprevir have been available in clinical practice [@B7], [@B21]-[@B23]. The addition of telaprevir or boceprevir to peginterferon plus ribavirin resulted in significantly higher rates of SVR in previously treated patients with chronic HCV genotype 1 infection [@B7], [@B21]-[@B23]. It will require more time until the more frequent use of DAAs for the treatment of HCV genotype 2 patients will become possible [@B24], [@B25]. Until then, we have to retreat HCV genotype 2-infected patients with peginterferon alfa-2a plus ribavirin for 24-48 weeks.

Recently, it was reported by several groups that genetic variations in IL28B-SNP predict HCV genotype 1 treatment-induced viral clearance [@B7], [@B26]-[@B29]. Yu et al. [@B30] reported that rs8099917 TT genotype is significantly independently predictive of RVR, which is the single best predictor of SVR, in Asian HCV genotype 2 patients. Further study will be needed.

In conclusion, we showed that retreatment of HCV genotype 2-infected Japanese patients with peginterferon alfa-2a plus ribavirin for 24-48 weeks resulted in 60 to 66.6% SVR in patients previously treated with (peg-)interferon monotherapy and in 69.9% SVR in relapsers previously treated with peginterferon plus ribavirin, which supports the previous reports [@B12], [@B13]. Attention should be paid to certain patients with unique features. Selection of patients according to previous treatment could lead to optimal therapy in HCV genotype 2 treatment-experienced patients.
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cEVR

:   Complete early virological response

DAA

:   Direct-acting antiviral

HCC

:   Hepatocellular carcinoma

HCV

:   Hepatitis C virus

IL28B

:   Interleukin-28B

RVR

:   Rapid virological response

SNP

:   Single nucleotide polymorphism

SD

:   Standard deviation

SOC

:   Standard of care

SVR

:   Sustained virological response.

![Three females retreated with peginterferon alfa plus ribavirin and resulting in non-sustained virological response, in whose sera a single very low-titer fluctuation of HCV RNA from negative to positive was detected after HCV RNA had been undetected. (a) Case 1, 68 years, female, IL28Brs8099917 TT. She was previously treated with peginterferon alfa-2a for 48 weeks, with details unknown. (b) Case 2, 58 years, female, IL28Brs8099977, not determined. She was previously treated with peginterferon alfa-2a for 48 weeks, with relapse. (c) Case 3, 58 years, female, IL28Brs8099917 TG. She was previously treated with peginterferon alfa-2b plus ribavirin, with details unknown. HCV RNA was determined by COBAS TaqMan HCV test (Roche), with levels ranging from 1.2 to 7.8 log IU/mL [@B16].](ijmsv10p0043g01){#F1}

###### 

Baseline and demographic characteristics of patients in the present study

  ---------------------------------------- --------------
  Number of patients                       29
  Age (years)                              60.1 ± 8.6
  Gender (male/female)                     15/14
  Body mass index (kg/m^2^)                26.2 ± 3.6
  HCV RNA (log IU/mL)                      5.5 ± 2.0
  ALT (IU/L)                               57.8 ± 50.7
  γ-GTP (IU/L)                             46.0 ± 40.7
  AFP (ng/mL)                              5.7 ± 3.4
  Leukocyte count (/mm^3^)                 4940 ± 1670
  Hemoglobin (g/dL)                        14.0 ± 1.6
  Platelet count (x10^4^/mm^3^)            16.2 ± 5.2
  *Treatment response*                     
  Duration of treatment (\~24/48/72 wks)   9/18/2
  RVR rates, %                             34.4 (10/29)
  HCV RNA negativity at 8 wks              81.4 (22/27)
  EVR rates, %                             88.8 (24/27)
  SVR rates, %                             62.0 (18/29)
  ---------------------------------------- --------------

Data are expressed as mean ± SD. ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transferase; AFP, alpha-fetoprotein; RVR, rapid virological response; EVR, early virological response; SVR, sustained virological response.

###### 

Baseline and demographic characteristics of SVR- and non-SVR-retreated patients

                                           SVR            Non-SVR       *P*-value\*
  ---------------------------------------- -------------- ------------- -------------
  Number of patients                       18             11            N.S.
  Age (years)                              60.0 ± 10.0    60.3 ± 6.3    N.S.
  Gender (male/female)                     8/10           7/3           N.S.
  Body mass index (kg/m^2^)                26.0 ± 3.4     26.5 ± 4.0    N.S.
  HCV RNA (log IU/mL)                      5.5 ± 1.9      5.5 ± 2.1     N.S.
  ALT (IU/L)                               57.8 ± 50.7    55.6 ± 52.8   N.S.
  γ-GTP (IU/L)                             46.0 ± 40.7    30.4 ± 17.6   N.S.
  AFP (ng/mL)                              5.7 ± 3.4      6.2 ± 5.7     N.S.
  Leukocyte count (/mm^3^)                 4940 ± 1670    4670 ± 940    N.S.
  Hemoglobin (g/dL)                        14.0 ± 1.6     13.6 ± 2.0    N.S.
  Platelet count (x10^4^/mm^3^)            16.2 ± 5.2     12.6 ± 4.1    0.061
  *Treatment response*                                                  
  Duration of treatment (\~24/48/72 wks)   6/11/1         3/7/1         N.S.
  RVR rates, %                             44.4 (8/18)    18.1 (2/11)   N.S.
  HCV RNA negativity at 8 wks              88.8 (16/18)   66.6 (6/9)    N.S.
  EVR rates, %                             88.8 (16/18)   88.8 (8/9)    N.S.
  Adherence (≥80/≥80/≥80), yes             44.4 (8/18)    54.5 (6/11)   N.S.

Data are expressed as mean ± SD. \**P*-value, between groups with and without SVR by Student\'s t-test or chi-square test; N.S., not statistically significant; ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transferase; AFP, alpha-fetoprotein; RVR, rapid virological response; EVR, early virological response; SVR, sustained virological response; adherence was classified according to the previous report [@B19].

###### 

Previous treatment response and SVR rates in 25 retreated patients

  --------------------------------------------------------------------------------------------------------------------------------
  Number of patients   Previous treatment\                      Formula of retreatment                             SVR rates (%)
                       (Treatment response)                                                                        
  -------------------- ---------------------------------------- -------------------------------------------------- ---------------
  6                    Peginterferon alfa-2a (NR)               Peginterferon alfa-2a plus ribavirin (\~24wks)     66.6

  1                    Peginterferon plus ribavirin (NR)        Peginterferon alfa-2a plus ribavirin (\~24wks)     0

  5                    (Peg-)interferon (relapse)               Peginterferon alfa-2a plus ribavirin (\~48wks)     60

  13                   Peginterferon plus ribavirin (relapse)   Peginterferon alfa-2a plus ribavirin (24\~48wks)   69.9
  --------------------------------------------------------------------------------------------------------------------------------

NR, non-response
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